Exact Sciences Corporation
EXASNASDAQHealthcare
$104.91
+$0.00(+0.00%)
Market Cap$20.0B
P/E Ratio—
52W High$104.98
52W Low$38.81
Exact Sciences Corporation (EXAS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EXAS · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 13, 2026EPS Actual
-$0.45
Est. -$0.11 · -316.9%
Revenue
$0.88B
Est. $0.86B · +2.0%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 13, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
EXAS reports quarterly as a NASDAQ-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.37
Rev. $0.36B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.37
Rev. Est.$0.36B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 13, 2026 | -$0.11 | -$0.45 | -316.9% | $0.88B | $0.86B | +2.0% |
| ▲ Q4 FY2025 | Nov 3, 2025 | -$0.06 | $0.24 | +492.0% | $0.85B | $0.81B | +5.0% |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.02 | $0.22 | +1200.0% | $0.81B | $0.81B | +0.1% |
| ▲ Q2 FY2025 | May 1, 2025 | -$0.37 | -$0.21 | +43.2% | $0.71B | $0.69B | +2.6% |
| ▲ Q1 FY2025 | Feb 19, 2025 | -$0.29 | -$0.06 | +79.3% | $0.71B | $0.70B | +2.2% |
| ▼ Q4 FY2024 | Nov 5, 2024 | -$0.20 | -$0.21 | -7.2% | $0.71B | $0.72B | -1.1% |
| ▲ Q3 FY2024 | Jul 31, 2024 | -$0.37 | -$0.09 | +75.7% | $0.70B | $0.69B | +1.3% |
| ▼ Q2 FY2024 | May 8, 2024 | -$0.47 | -$0.50 | -5.3% | $0.64B | $0.63B | +1.6% |
Q1 FY2026
Feb 13, 2026Miss
EPS Actual
-$0.45
EPS Est.
-$0.11
EPS Surpr.
-316.9%
Revenue
$0.88B
Q4 FY2025
Nov 3, 2025Beat
EPS Actual
$0.24
EPS Est.
-$0.06
EPS Surpr.
+492.0%
Revenue
$0.85B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
$0.22
EPS Est.
-$0.02
EPS Surpr.
+1200.0%
Revenue
$0.81B
Q2 FY2025
May 1, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$0.37
EPS Surpr.
+43.2%
Revenue
$0.71B
Q1 FY2025
Feb 19, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.29
EPS Surpr.
+79.3%
Revenue
$0.71B
Q4 FY2024
Nov 5, 2024Miss
EPS Actual
-$0.21
EPS Est.
-$0.20
EPS Surpr.
-7.2%
Revenue
$0.71B
Q3 FY2024
Jul 31, 2024Beat
EPS Actual
-$0.09
EPS Est.
-$0.37
EPS Surpr.
+75.7%
Revenue
$0.70B
Q2 FY2024
May 8, 2024Miss
EPS Actual
-$0.50
EPS Est.
-$0.47
EPS Surpr.
-5.3%
Revenue
$0.64B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.53 | $0.56 | $0.58 | 1 |
| Q3 FY2028 | $0.43 | $0.45 | $0.47 | 1 |
| Q2 FY2028 | $0.46 | $0.49 | $0.51 | 1 |
| Q1 FY2028 | $0.05 | $0.05 | $0.05 | 1 |
| Q4 FY2027 | $0.37 | $0.39 | $0.41 | 1 |
| Q3 FY2027 | $0.41 | $0.43 | $0.45 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.1B | $1.2B | $1.2B | 2 |
| Q3 FY2028 | $1.1B | $1.2B | $1.2B | 1 |
| Q2 FY2028 | $1.0B | $1.1B | $1.1B | 1 |
| Q1 FY2028 | $0.9B | $1.0B | $1.0B | 2 |
| Q4 FY2027 | $1.1B | $1.1B | $1.1B | 3 |
| Q3 FY2027 | $1.0B | $1.1B | $1.1B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 13, 2026 | -316.9% | $103.23 | $103.24 | +0.01% |
| ▲ Q4 FY2025 | Nov 3, 2025 | +492.0% | $64.69 | $66.98 | +3.54% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +1200.0% | $47.36 | $46.91 | -0.95% |
| ▲ Q2 FY2025 | May 1, 2025 | +43.2% | $45.64 | $47.16 | +3.33% |
| ▲ Q1 FY2025 | Feb 19, 2025 | +79.3% | $49.63 | $50.48 | +1.71% |
| ▼ Q4 FY2024 | Nov 5, 2024 | -7.2% | $71.13 | $71.51 | +0.53% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +75.7% | $46.58 | $45.68 | -1.93% |
| ▼ Q2 FY2024 | May 8, 2024 | -5.3% | $61.41 | $59.48 | -3.14% |
Q1 FY2026+0.01%
Report Date
Feb 13, 2026
EPS Beat/Miss
-316.9%
Price Before
$103.23
Price After
$103.24
Q4 FY2025+3.54%
Report Date
Nov 3, 2025
EPS Beat/Miss
+492.0%
Price Before
$64.69
Price After
$66.98
Q3 FY2025-0.95%
Report Date
Aug 6, 2025
EPS Beat/Miss
+1200.0%
Price Before
$47.36
Price After
$46.91
Q2 FY2025+3.33%
Report Date
May 1, 2025
EPS Beat/Miss
+43.2%
Price Before
$45.64
Price After
$47.16
Q1 FY2025+1.71%
Report Date
Feb 19, 2025
EPS Beat/Miss
+79.3%
Price Before
$49.63
Price After
$50.48
Q4 FY2024+0.53%
Report Date
Nov 5, 2024
EPS Beat/Miss
-7.2%
Price Before
$71.13
Price After
$71.51
Q3 FY2024-1.93%
Report Date
Jul 31, 2024
EPS Beat/Miss
+75.7%
Price Before
$46.58
Price After
$45.68
Q2 FY2024-3.14%
Report Date
May 8, 2024
EPS Beat/Miss
-5.3%
Price Before
$61.41
Price After
$59.48
Avg Beat Reaction+1.14%
Avg Miss Reaction-0.87%
Beat Rate5 / 8 quarters
Largest Move+3.54% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EXAS ends December
Exact Sciences Corporation (EXAS) most recently reported earnings on February 13, 2026 for Q1 FY2026, posting EPS of $-0.45 — missing the analyst consensus of $-0.11 by -316.9%. The next EXAS earnings date is expected around September 1, 2026.
Each quarter, investors track EXAS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EXAS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EXAS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EXAS earnings · 5 questionsExact Sciences Corporation's next earnings report is expected around September 1, 2026. EXAS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EXAS historically reports after market close (AMC).
EXAS earnings datewhen is EXAS earningsEXAS next earnings datewhen does EXAS report earningsEXAS earnings calendar
▸ Source: FMP · Exact Sciences Corporation SEC filings · US GAAP · Exact Sciences Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026